Voretigene neparvovec is a gene therapy approved for the treatment of patients with an autosomal recessive retinal dystrophy due to confirmed biallelic RPE65 variants (RPE65-IRDs). This evidence concerns the gene RPE65 and respiratory distress syndrome in premature infants.